

First reports of adverse drug reactions

© Springer Nature Switzerland AG 2018

Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries of adverse drug reaction news sourced from journals, scientific

meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

Table 1 First published reports of adverse drug reactions recently identified by *Reactions Weekly*

Drug and adverse reaction	Reference
Abiraterone acetate: bilateral choroidal metastases (serious)	Kourie HR, Antoun J, Bteich F, et al. Bilateral choroidal metastases from prostate cancer revealed in a patient under abiraterone—fourteen years after diagnosis. <i>Gulf J Oncolog.</i> 2016;21(May):67–9. http://www.gffcc.org/journal/docs/issue21/pp67-69_HR_Kourie.pdf
Chlordiazepoxide: acute onset bilateral myopia (serious)	Hamid A, Maalagh M, Ghanbari M, et al. Acute onset bilateral myopia induced by chlordiazepoxide. <i>Trends Pharmaceut Sci.</i> 2018;4(2):85–6 https://doi.org/10.1111/tips.v4i2.179 .
Nivolumab: cold agglutinin syndrome (serious)	Hasanov M, Konoplev SN, Rojas Hernandez CM. Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. <i>Bood Adv.</i> 2018;2(15):1865–8. https://doi.org/10.1182/bloodadvances.2018019000
Nivolumab: scleroderma-like skin changes (serious)	Tjarks BJ, Bleeker JS, Kerkvliet AM, et al. Scleroderma-like skin changes induced by checkpoint inhibitor therapy [abstract]. <i>Am J Dermatopathol.</i> 2018;40(6):e92. https://doi.org/10.1097/dad.0000000000001163
Palbociclib: cutaneous and GI leukocytoclastic vasculitis (serious)	Guillemois S, Patsouris A, Peyraga G, et al. Cutaneous and gastrointestinal leukocytoclastic vasculitis induced by palbociclib in a metastatic breast cancer patient: a case report. <i>Clin Breast Cancer</i> 2018;18(5):e755–8. https://doi.org/10.1016/j.clbc.2018.07.006
Venlafaxine: prostatism	Gundogmus I, Ispir M, Bakkal O, et al. Venlafaxine-induced prostatism: a case report. <i>Psychiatr Clin Psychopharmacolog.</i> 2017;27(2):197–8. https://doi.org/10.1080/24750573.2017.1296398

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage